VCAN – A novel prognostic marker for gastric cancer

CURRENT STATUS: POSTED

Helen Barong Binang
Second Hospital of Shandong University

Yun-shan Wang
Second Hospital of Shandong University

Marvin Anemey Tewara
Healthcare Big Data Medical Research Institute, Shandong University

Weiqiang Lin
Health Care Big Data Medical Research Institute, Shandong University

Lutao Du
Second Hospital of Shandong University

Chuanxin Wang
cxwang@sdu.edu.cn Corresponding Author

DOI:
10.21203/rs.2.14320/v1

SUBJECT AREAS
Oncology Cancer Biology

KEYWORDS
VCAN, oncogene, prognostic marker, gastric cancer, chemotherapy.
Abstract
Background Versican (VCAN) is a large aggregating extracellular matrix proteoglycan implicated in the pathogenesis of most human cancers but its role in gastric cancer is not yet elucidated. We designed the present study to investigate the expression, prognostic value, relationship between genetic alterations and patient’s outcome, disease associations, as well as genetic and protein interactions of VCAN in gastric cancer. Methods Expression of VCAN in tumor and normal tissues was studied with ONCOMINE, UALCAN, and GEPIA databases and the human protein atlas. UALCAN, GEPIA, OncoLnc and Kaplan-Meier plotter were used to assess the prognostic values of VCAN in gastric cancer. Subgroup analysis of the clinical significance of VCAN in gastric cancer was done using Kaplan-Meier plotter. Genetic alterations of VCAN and their associations with patient’s outcome were studied with cBioPortal. Open targets platform was used to study diseases associated with VCAN, GeneMANIA was used to obtain the neighbor genes interaction network of VCAN, and STRING was used to examine VCAN interaction with other proteins. Results VCAN was upregulated and associated with clinical cancer stages. High VCAN expression predicted unfavorable outcome for all patients; subgroup analysis showed worse outcomes for patients treated with surgery or other adjuvants (other than 5-FU based adjuvant) but better outcome for patients treated with 5-FU based adjuvant, associating VCAN expression with chemosensitivity to 5-FU based adjuvants, but chemoresistance to other adjuvants. Genetic alteration of VCAN correlated with a favorable outcome in terms of disease-free survival for patients. Also, open targets platform showed that VCAN is associated with gastric cancer and is a potential therapeutic target for the disease. Finally, interaction of VCAN with neighbor genes and proteins revealed that VCAN interacts with genes and proteins that drive tumorigenesis and cancer progression. Conclusion The results of this study show that VCAN is an oncogene in gastric cancer whose expression can be applied as a biomarker for prognostic prediction, selection of appropriate chemotherapy drugs/monitoring of treatment response, and is a potential therapeutic target for gastric cancer.

Background
The discovery of genes that contribute to cancer has been an extremely important development for
cancer research. This is because carcinogenesis is mostly genetic and majority of cancers are observed to have some type of genetic alteration(1). Overwhelming evidence has it that the provision of lasting panacea for human cancers lies in the identification of tumor associated genes which can be markers of patient’s outcome and targets for therapy(2-5). So far, aberrant gene expressions have been implicated to cause malignant signatures in gastric cancer and abnormally expressed genes are thought to be potential tumor markers and therapeutic targets(6-8). Identification of genes that fuel tumorigenic processes is pertinent to the development of personalized therapies and disease management plans.

Versican (VCAN), a member of the large chondroitin sulfate proteoglycan family that interacts with hyaluronan is a large aggregating extracellular matrix proteoglycan, about 900 kDa, with 15-20 chondroitin sulfate side chains(9,10). It has several active domains that influences its interactions with certain biological and pathological processes, and functions in extracellular matrix assembly and remodeling, anti-adhesion, as well as tumor cell proliferation, and migration(11). It is suggested to be involved in the development and progression of several malignancies due to its frequent expression in human cancers(12), and several studies have also validated its role in carcinogenesis - it is implicated in the pathogenesis of colorectal cancer, breast cancer, benign prostatic hyperplasia, skin cancer, oral squamous cell carcinoma, early-stage prostate cancer, and in leiomyomas, amongst others and associated with survival outcomes(11,13-18). However, its role in gastric cancer is not yet explained. In this study, we investigated the expression and clinical significance of VCAN to explicate its role and potential as a biomarker for gastric cancer.

Materials And Methods

Ethics statement

Our study was approved by the Ethics Committee of the Second Hospital of Shandong University. Since all data were obtained from publicly accessible online databases, all written informed consent would have already been obtained.

ONCOMINE, UALCAN and GEPIA analyses

The mRNA levels of VCAN in 20 different cancer types were determined through analysis in
ONCOMINE database (www.oncomine.org)(19). Expression of VCAN in primary tumor tissues and normal tissues were validated in UALCAN (http://ualcan.path.uab.edu)(20) and gene expression profiling interactive analysis (GEPIA) (http://gepia.cancer-pku.cn)(21) databases. Difference of transcriptional expressions was compared by students’ t test and P < 0.05 was considered as statistically significant.

The Human Protein Atlas
The human protein atlas is a website that contains immunohistochemistry-based expression data for 20 most common kinds of cancers(22). Direct comparison of protein expression of VCAN between normal human stomach tissue and gastric cancer tissue was examined by immunohistochemistry image on the human protein atlas (https://www.proteinatlas.org).

Survival analysis
Datasets from four independent cohorts were utilized for analysis of VCAN expression as a prognostic factor for gastric cancer, namely: UALCAN, GEPIA, OncoLnc (www.oncolnc.org/)(23), and Kaplan-Meier plotter (http://kmplot.com/analysis/)(24–26) (Affymetrix ID: 204619_s_at). Subgroup analysis was performed using Kaplan-Meier plotter, and the survival analysis results of 876 gastric cancer tissue samples from The Cancer Genome Atlas (TCGA) are available at the Kaplan Meier plotter database. P < 0.05 was considered as statistically significant.

CBioPortal analysis
Gene alteration frequency of VCAN in stomach adenocarcinoma (STAD) was performed using the CBioPortal for Cancer Genomics (http://www.cbioportal.org/)(27) database. Genetic mutations in VCAN and its association with disease-free survival (DFS) was displayed as Kaplan-Meier plots and log-rank test.

Open Targets Platform
Diseases associated with VCAN based on pathways and systems biology were examined using the Open Targets Platform (www.targetvalidation.org/) which is a comprehensive and robust data integration platform for access to and visualization of potential drug targets associated with diseases(28).
GeneMANIA and STRING analyses

GeneMANIA (http://www.genemania.org)(29) was used to conduct correlation analysis of VCAN at the gene level. STRING (https://string-db.org/)(30) database was used to conduct correlation analysis of VCAN at the protein level.

Results

**VCAN is upregulated in gastric cancer and correlates with cancer stage:**

To examine the role of VCAN in gastric cancer, we first studied its expression in tumor tissues and normal tissues using three independent cohorts – ONCOMINE, UALCAN, and GEPIA datasets. VCAN was upregulated in all three datasets (Figure 1A – 1C). Pan cancer analysis in ONCOMINE showed that VCAN is upregulated in most human cancers and shows that currently, seven independent datasets report VCAN upregulation in gastric cancer (Figure 1A). Expression of VCAN also correlated with tumor stage, expression increased with increase in stage and the highest expression was found in the most advanced cancer stage (stage 4) (Figure 1B – 1C). We also examined the protein expression of VCAN in normal stomach and gastric cancer using the human protein atlas. VCAN was more highly expressed in cancer tissues than normal tissues as indicated by high antibody staining in cancer and medium antibody staining in normal tissues (Figure 1D). Together, these results show that VCAN is upregulated in gastric cancer and correlates with cancer stage.

**High VCAN expression predicts worse outcomes for patients; and VCAN expression is associated with response to chemotherapy:**

Using four independent datasets, we studied the prognostic value of VCAN in gastric cancer. High VCAN expression correlated with poor prognosis for patients in all four datasets (all P < 0.05) (Figure 2A – 2D). Subgroup analysis in Kaplan-Meier plotter database showed that shorter OS and PPS were found in all patients (HR=1.32, P=0.0033, and HR=1.37, P=0.0086 respectively), intestinal type patients (HR=2, P=2.4e-05, and HR=1.81, P=0.0044 respectively), diffuse type patients (HR=1.77, P=0.0097, and HR=1.72, P=0.0045 respectively), patients treated with surgery only (HR=1.9, P=1.1e-05, and HR=1.77, P=0.00026 respectively), or other adjuvant (other 5-FU based adjuvant) only (HR=3.04, P=0.0091 and HR=2.72, P=0.021 respectively). However, longer OS and PPS times
were observed in patients treated with 5-FU based adjuvant only (HR=0.63, P=0.023, and HR=0.56, P=0.0059 respectively) (Figure 3A-3F). Together these results show the prognostic value of VCAN in gastric cancer, and its association with response to chemotherapy.

**Genetic alteration in VCAN is a marker of favorable disease-free survival (DFS) for patients:**

Previous studies have linked alterations in certain genes with carcinogenesis(31). We investigated possible associations between genetic alteration in VCAN with disease-free survival (DFS) of patients. Figure 4A shows a summary of genetic alterations of VCAN in gastric cancer. In the 1365 sequenced STAD patients, genetic alteration was found in 115 patients and the mutation rate was 9% (Figure 4B). Kaplan-Meier plot and log-rank test showed that cases with gene alterations had longer DFS times than those without alterations (P=3.055e-3) (Figure 4C). These results show that genetic alterations in VCAN are associated with DFS of gastric cancer patients.

**VCAN is a potential target for gastric cancer therapy:**

In other to identify genes that are potential targets for treatment of malignant disorders, the open targets platform provides a means to score and rank target-disease associations by bringing together multiple data types to assist in the identification and prioritization of targets for further investigation(28). Surfing this platform, we found VCAN associated with gastric cancer and other diseases and the therapeutic area also reveals the possibility of VCAN as a target for gastric cancer therapy (Figure 5A – 5B).

Next, we constructed a network for VCAN with the structure or function of neighboring genes using GeneMANIA. The results showed that 20 genes – ANOS1, BCAN, CCL8, CD14, CD44, COL3A1, CXCL12, FBLN2, FBN1, HAPLN1, ITGAM, MMP9, SELP, SPARC, TLR1, TLR2, TLR6, TP53, TNFAIP6 – were closely associated with VCAN (Figure 6A).

Finally, we examined the interaction of VCAN protein with other human proteins using STRING database. The results revealed that VCAN interacts closely with 10 proteins – BCAN, BGN, CDH2, CHST11, CSPG4, DCN, FBN1, FN1, GPC1, and TLR2. Together, these results show that VCAN is a potential target for gastric cancer therapy; and also shows the neighbor gene interaction and protein
interaction networks of VCAN.

Discussion

Gastric cancer has witnessed some advancements in terms of treatment, especially with the introduction of trastuzumab (a HER2 antibody) for the treatment of HER2 positive patients(32). However, only less than 20% of patients can benefit from this regimen(33) and as such gastric cancer is still one of the major causes of cancer-related deaths worldwide. Most deaths are due to lack of understanding of the genetic and molecular alterations and interactions that fuel tumorigenesis and progression; and non-availability of markers for detection, prediction of outcome, and targets for therapy.

In the present study, we investigated the role of VCAN in gastric carcinogenesis and found that VCAN is upregulated in gastric cancer and its expression was associated with, and increased with cancer stage. Overexpression of VCAN may have a role in initiation and progression of gastric cancer since changes were observed between normal and pathological stages and between each stage. VCAN may play an oncogenic role in gastric cancer, promoting disease progression from early to advance stage in accordance with several reports linking upregulated gene expressions with carcinogenesis and disease progression(34–40). Immunohistochemical examination of VCAN expression also confirmed our findings, with a higher protein expression in cancer tissues than normal tissues.

Elevated expression of VCAN predicted worse outcomes for patients as shorter survival times were observed in the high expression group compared with the low expression group. Again, previous evidence had documented the associations between upregulated gene expressions and poor patients outcome(41–44) and VCAN had been reported as an unfavorable prognostic marker in oral squamous cell carcinoma and endometrial cancer(11,45). VCAN expression in gastric cancer may be a potential diagnostic tool and a marker of poor outcome for patients.

Gastric cancer exhibits strong heterogeneity and varied sensitivity to chemotherapy drugs, with a strong need for the development of individualized therapies. Regimens available for the treatment of gastric cancer include (but not limited to) 5-fluorouracil (5-FU), platinum, taxane, irinotecan and anthracycline, with 5-FU being the most common(46,47). Selection of efficient chemotherapy drugs,
design of optimal chemotherapy regimens and prediction of treatment response for gastric cancer requires comprehensive analysis and identification of chemotherapy-associated genes (47). We examined the effect of VCAN on various subgroups of patients especially with regard to treatment response. Interestingly, high VCAN expression correlated with worse outcomes for patients treated with surgery only or other adjuvants (other than 5-FU based adjuvant) only. However, patients expressing high VCAN who were treated with 5-FU based adjuvants had longer survival times than the low expression group. This shows that high expression of VCAN may be associated with chemosensitivity to 5-FU based adjuvants but chemoresistance to other adjuvants. VCAN expression may be applicable in determining appropriate treatment options for gastric cancer patients. Gene alterations such as mutations, amplifications and deep deletions have been reported to influence cancer patients outcomes(31,48). We found 9% alteration of VCAN in gastric cancer and this was associated with better outcome in terms of DFS for patients. Hence, genetic alterations of VCAN may be a marker of favorable outcome for patients. Using the open targets platform also, we found VCAN associated with gastric cancer and the therapeutic area identified VCAN as a potential therapeutic target for gastric cancer. Neighbor genes interaction network revealed associations of VCAN with genes that function in tissue development (such as ANOS1, BCAN, FBLN2, and MMP9) and those that regulate metastasis by influencing cell-cell interactions, cell adhesion and migration (such as CD44, COL3A1, FBN1, HAPLN1, SELL, and SPARC), further showing the involvement of VCAN in tumorigenesis and disease progression. Interestingly also, VCAN closely interacted with a good number of immunity-related genes (such as CCL8, CD14, CXCL12, ITGAM, SELP, TLR1, TLR2, TLR6, and TNFAIP6). This is particularly important because cancer is known to weaken the immune system, and there is evidence that regulatory T cells may be induced by tumors and downregulate the immune system response to tumor antigens, thereby incapacitating the immune system and facilitating disease progression(49). On the other hand, this association may be due to the tumorigenic nature of VCAN attracting enormous immune attention. We therefore hypothesize a possible VCAN-mediated immunogenicity and/or VCAN-mediated immune compromise during cancer progression. VCAN interactions at the protein level further validated this. VCAN interacted closely with
proteins that function in tissue growth, development and regeneration (such as BGN, BCAN, and GPC1) and those involved in growth, adhesion and migration of tumor cells (such as CSPG4, FN1, FBN1, and CDH2) as well as TLR2 involved in innate and adaptive immunity.

This study had one major limitation - all the data analyzed were retrieved from online databases, and as such, further studies with larger sample sizes are required to validate our findings. Nevertheless, we demonstrated that VCAN is upregulated in gastric cancer and associated with clinical cancer stages. High VCAN expression predicted unfavorable outcome for patients, but better outcome for patients treated with 5-FU based adjuvant; and genetic alteration of VCAN is a positive marker for patients. Finally, VCAN is associated with genes and proteins that drive tumorigenesis and cancer progression, and has potential clinical application in the management and treatment of gastric cancer patients.

Conclusion
The results of this study show that VCAN is an oncogene in gastric cancer whose expression can be applied as a biomarker for prognostic prediction, selection of appropriate chemotherapy drugs/monitoring of treatment response, and is a potential therapeutic target for gastric cancer.

Abbreviations
5-FU: 5-fluorouracil; DFS: Disease-free survival; GEPIA: Gene expression profiling interactive analysis; HER2: Human epidermal growth factor receptor 2; OS: Overall survival, PPS: Post-progression survival; STAD: Stomach adenocarcinoma; TCGA: The Cancer Genome Atlas; VCAN: Versican.

Declarations

Ethics approval and consent to participate
This study was approved by the Ethics Committee of the Second Hospital of Shandong University.

Consent for publication
Not applicable

Availability of data and materials
The datasets generated during and/or analyzed during the current study are available in the respective repositories [persistent web links to datasets and reference numbers are stated in the materials and methods section].
**Competing interests**

The authors declare that they have no competing interests.

**Funding**

This work was supported by grant from the Fundamental Research Fund of Shandong University (2017BTS01, 2018JC002 and 2017JC031) and the Key Research and Development Program of Shandong Province (2018FYJH0505).

**Authors’ contributions**

HBB, YW and CW conceived and designed the project. HBB prepared the figures and wrote the manuscript. HBB, YW, MAT, WL and LD analyzed/interpreted the data and revised the manuscript. All authors read and approved the final manuscript.

**Acknowledgement**

The authors acknowledge Shandong University for the study support.

**References**

1. Weir B, Zhao X, Meyerson M. Somatic alterations in the human cancer genome. Cancer Cell. 2004 Nov;6(5):433–8.

2. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, et al. A census of human cancer genes. Nature Reviews Cancer. 2004 Mar;4(3):177–83.

3. Slavov N, Dawson KA. Correlation signature of the macroscopic states of the gene regulatory network in cancer. Proceedings of the National Academy of Sciences. 2009 Mar 17;106(11):4079–84.

4. Benvenuti S, Arena S, Bardelli A. Identification of cancer genes by mutational profiling of tumor genomes. FEBS Letters. 2005 Mar 21;579(8):1884–90.

5. Tian D. Remarkable difference of somatic mutation patterns between oncogenes and tumor suppressor genes. Oncology Reports [Internet]. 2011 Sep 1 [cited 2019 Aug 18]; Available from: http://www.spandidos-publications.com/10.3892/or.2011.1443

6. Xu M, Wang Y, Weng W, Wei P, Qi P, Zhang Q, et al. A Positive Feedback Loop of
IncRNA- PVT1 and FOXM1 Facilitates Gastric Cancer Growth and Invasion. Clinical Cancer Research. 2017 Apr 15;23(8):2071-80.

7. Tian X, Zhu X, Yan T, Yu C, Shen C, Hong J, et al. Differentially Expressed IncRNAs in Gastric Cancer Patients: A Potential Biomarker for Gastric Cancer Prognosis. Journal of Cancer. 2017;8(13):2575-86.

8. Han W, Zhang Z, He B, Xu Y, Zhang J, Cao W. Integrated analysis of long non-coding RNAs in human gastric cancer: An in silico study. Ahmad A, editor. PLOS ONE. 2017 Aug 25;12(8):e0183517.

9. Sotoodehnejadmatalahi F, Burke B. Structure, Function and Regulation of Versican: The Most Abundant Type of Proteoglycan in the Extracellular Matrix. :11.

10. LaPierre DP, Lee DY, Li S-Z, Xie Y-Z, Zhong L, Sheng W, et al. The Ability of Versican to Simultaneously Cause Apoptotic Resistance and Sensitivity. Cancer Research. 2007 May 15;67(10):4742–50.

11. Pukkila M, Kosunen A, Ropponen K, Virtaniemi J, Kellokoski J, Kumpulainen E, et al. High stromal versican expression predicts unfavourable outcome in oral squamous cell carcinoma. Journal of Clinical Pathology. 2006 May 26;60(3):267–72.

12. Fanhchaksai K, Okada F, Nagai N, Pothacharoen P, Kongtawelert P, Hatano S, et al. Host stromal versican is essential for cancer-associated fibroblast function to inhibit cancer growth: Stromal versican inhibits tumor growth. International Journal of Cancer. 2016 Feb 1;138(3):630–41.

13. Keire PA, Bressler SL, Lemire JM, Edris B, Rubin BP, Rahmani M, et al. A Role for Versican in the Development of Leiomyosarcoma. Journal of Biological Chemistry. 2014 Dec 5;289(49):34089-103.

14. Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer. - PubMed - NCBI.html.
https://clincancerres.aacrjournals.org/content/clincanres/4/4/963.full.pdf (Accessed August 12 2019).

15. Hosseini SM, Jafary F, Hosseini M, Mahjoubi F. VCAN gene expression and its association with tumor stage and lymph node metastasis in colorectal cancer patients. Biomedical Research [Internet]. 2018 [cited 2019 Aug 16];29(6). Available from: http://www.alliedacademies.org/articles/vcan-gene-expression-and-its-association-with-tumor-stage-and-lymph-node-metastasis-in-colorectal-cancer-patients-9883.html

16. Du WW, Fang L, Yang X, Sheng W, Yang BL, Seth A, et al. The Role of Versican in Modulating Breast Cancer Cell Self-renewal. Molecular Cancer Research. 2013 May;11(5):443–55.

17. True LD, Hawley S, Norwood TH, Braun KR, Evanko SP, Chan CK, et al. The accumulation of versican in the nodules of benign prostatic hyperplasia. The Prostate. 2009 Feb 1;69(2):149–58.

18. Kunisada M, Yogianti F, Sakumi K, Ono R, Nakabeppu Y, Nishigori C. Increased Expression of Versican in the Inflammatory Response to UVB- and Reactive Oxygen Species-Induced Skin Tumorigenesis. The American Journal of Pathology. 2011 Dec;179(6):3056–65.

19. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, et al. ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform. Neoplasia. 2004 Jan;6(1):1–6. https://doi.org/10.1016/S1476-5586(04)80047-2.

20. Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK, et al. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017 Aug;19(8):649–58. https://doi.org/10.1016/j.neo.2017.05.002
21. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Research. 2017 Jul 3;45(W1):W98-102. https://doi.org/10.1093/nar/gkx247.

22. Asplund A, Edqvist P-HD, Schwenk JM, Pontén F. Antibodies for profiling the human proteome-The Human Protein Atlas as a resource for cancer research. PROTEOMICS. 2012 Jul;12(13):2067–77. https://doi.org/10.1002/pmic.201100504.

23. Anaya J. OncoLnc: Linking TCGA survival data to mRNAs, miRNAs, and IncRNAs. :20. https://doi.org/10.7717/peerj-cs.67.

24. Szász AM, Lánczky A, Nagy Á, Förster S, Hark K, Green JE, et al. Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget [Internet]. 2016 Aug 2 [cited 2019 Aug 21];7(31). Available from: http://www.oncotarget.com/fulltext/10337. https://doi.org/10.18632/oncotarget.10337

25. Györffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Research and Treatment. 2010 Oct;123(3):725–31. https://doi.org/10.1007/s10549-009-0674-9.

26. Györffy B, Surowiak P, Budczies J, Lánczky A. Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer. Chellappan SP, editor. PLoS ONE. 2013 Dec 18;8(12):e82241. https://doi.org/10.1371/journal.pone.0082241.

27. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal. Science Signaling. 2013 Apr 2;6(269):pl1-pl1. https://doi.org/10.1126/scisignal.2004088
28. Carvalho-Silva D, Pierleoni A, Pignatelli M, Ong C, Fumis L, Karamanis N, et al. Open Targets Platform: new developments and updates two years on. Nucleic Acids Research. 2019 Jan 8;47(D1):D1056-65. https://doi.org/10.1093/nar/gky1133. https://doi.org/10.7717/peerj-cs.67.

29. Montojo J, Zuberi K, Rodriguez H, Bader GD, Morris Q. GeneMANIA: Fast gene network construction and function prediction for Cytoscape. F1000Research. 2014 Jul 1;3:153. https://doi.org/10.12688/f1000research.4572.1.

30. Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, et al. STRING v10: protein–protein interaction networks, integrated over the tree of life. Nucleic Acids Research. 2015 Jan 28;43(D1):D447–52. https://doi.org/10.1093/nar/gku1003.

31. Ning G, Huang Y-L, Zhen L-M, Xu W-X, Jiao Q, Yang F-J, et al. Transcriptional expressions of Chromobox 1/2/3/6/8 as independent indicators for survivals in hepatocellular carcinoma patients. Aging. 2018 Nov 27;10(11):3450–73.

32. Zhao J, Du P, Cui P, Qin Y, Hu C, Wu J, et al. LncRNA PVT1 promotes angiogenesis via activating the STAT3/VEGFA axis in gastric cancer. Oncogene. 2018 Jul;37(30):4094–109.

33. Shitara K, Yatabe Y, Matsuo K, Sugano M, Kondo C, Takahari D, et al. Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment. Gastric Cancer. 2013 Apr;16(2):261–7.

34. Kim G-C, Kwon H-K, Lee C-G, Verma R, Rudra D, Kim T, et al. Upregulation of Ets1 expression by NFATc2 and NFKB1/RELA promotes breast cancer cell invasiveness. Oncogenesis [Internet]. 2018 Nov [cited 2019 Jun 16];7(11). Available from: http://www.nature.com/articles/s41389-018-0101-3

35. Yuan Y, Sun S, Jiao N, Shu Y, Zhang Y. Upregulation of HOXA10 Protein Expression
Predicts Poor Prognosis for Colorectal Cancer. Genetic Testing and Molecular Biomarkers. 2018 Jun;22(6):390–7.

36. Zheng H, Jiang W, Tian T, Tan H, Chen Y, Qiao G, et al. CBX6 overexpression contributes to tumor progression and is predictive of a poor prognosis in hepatocellular carcinoma. Oncotarget [Internet]. 2017 Mar 21 [cited 2019 Jul 22];8(12). Available from: http://www.oncotarget.com/fulltext/14770

37. Uzan VRM, Lengert A van H, Boldrini É, Penna V, Scapulatempo-Neto C, Scrideli CA, et al. High Expression of HULC Is Associated with Poor Prognosis in Osteosarcoma Patients. London CA, editor. PLOS ONE. 2016 Jun 2;11(6):e0156774.

38. Li C, Li W, Zhang Y, Zhang X, Liu T, Zhang Y, et al. Increased expression of antisense IncRNA SPINT1-AS1 predicts a poor prognosis in colorectal cancer and is negatively correlated with its sense transcript. OncoTargets and Therapy. 2018 Jul;Volume 11:3969–78.

39. Yang Z-T, Li Z, Wang X-G, Tan T, Yi F, Zhu H, et al. Overexpression of Long Non-Coding RNA ZXF2 Promotes Lung Adenocarcinoma Progression Through c-Myc Pathway. Cellular Physiology and Biochemistry. 2015;35(6):2360–70.

40. Zheng S, Lv P, Su J, Miao K, Xu H, Li M. Overexpression of CBX2 in breast cancer promotes tumor progression through the PI3K/AKT signaling pathway. :15.

41. Yao XM, Tang JH, Zhu H, Jing Y. High expression of LncRNA CASC15 is a risk factor for gastric cancer prognosis and promote the proliferation of gastric cancer. Eur Rev Med Pharmacol Sci. 2017;21(24):5661–5667.

42. Li J, Lian Y, Yan C, Cai Z, Ding J, Ma Z, et al. Long non-coding RNA FOXP4-AS1 is an unfavourable prognostic factor and regulates proliferation and apoptosis in colorectal cancer. Cell Proliferation. 2017 Feb;50(1):e12312.

43. Yang Y-F, Pan Y-H, Tian Q-H, Wu D-C, Su S-G. CBX1 Indicates Poor Outcomes and
Exerts Oncogenic Activity in Hepatocellular Carcinoma. Translational Oncology. 2018 Oct;11(5):1110–8.

44. Crea F, Hurt EM, Farrar WL. Clinical significance of Polycomb gene expression in brain tumors. Molecular Cancer. 2010;9(1):265.

45. Kodama J, Hasengaowa, Kusumoto T, Seki N, Matsuo T, Ojima Y, et al. Prognostic significance of stromal versican expression in human endometrial cancer. Annals of Oncology. 2006 Nov 20;18(2):269–74.

46. Ma J, Shen H, Kapesa L, Zeng S. Lauren classification and individualized chemotherapy in gastric cancer. Oncology Letters. 2016 May;11(5):2959–64.

47. on behalf of the AGAMENON study group, Jiménez Fonseca P, Carmona-Bayonas A, Hernández R, Custodio A, Cano JM, et al. Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry. British Journal of Cancer. 2017 Sep;117(6):775–82.

48. Zhou Q, Hou C-N, Yang H-J, He Z, Zuo M-Z. Distinct expression and prognostic value of members of the epidermal growth factor receptor family in ovarian cancer. Cancer Management and Research. 2018 Dec;Volume 10:6937–48.

49. Standish LJ. Breast Cancer and the Immune System. 2010;16.

Figures
VCAN is upregulated in gastric cancer and associated with tumor stage; (A)The mRNA expression of VCAN in 20 different cancer types (cancer vs. normal tissue) was analyzed with ONCOMINE database. The number in each cell of the graph represents the number of
datasets with statistically significant mRNA over-expression (red) or down-expression (blue) of the target gene. The P value threshold is 0.01. (B, C) VCAN is upregulated and associated with cancer stage in UALCANC and GEPIA databases. Its expression increases with cancer stage and the highest mRNA expression was found in stage 4. (D) Representative immunohistochemistry images of VCAN in human cancer tissues and normal tissues (Human Protein Atlas). VCAN protein was more highly expressed in cancer tissues than normal tissues. *P < 0.05, ***P < 0.001

Figure 2

Prognostic value of VCAN in gastric cancer from four independent datasets. (A-D) High VCAN expression is associated with shorter survival times for all gastric cancer patients.
Subgroup analysis of prognostic value of VCAN in gastric cancer (Kaplan Meier Plotter). High VCAN expression predicted poor OS and PPS in (A) all patients, (B, C) intestinal type and diffuse type patients, (D, E) patients treated with surgery only and patients treated with other adjuvants only; but better OS and PPS in patients treated with 5-FU based adjuvant only (F).
Figure 4

Genetic alterations in VCAN and its association with disease-free survival (DFS) of patients (cBioPortal). (A) summary of alterations in VCAN. (B) OncoPrint visual summary of alteration on a query of VCAN. (C) Kaplan–Meier plots comparing DFS in cases with/without VCAN gene alterations.
Figure 5

Diseases associated with VCAN based on pathways and systems biology (Open Targets Platform). (A, B) VCAN is associated with gastric cancer and other diseases based on pathways and systems biology.
Figure 6

Neighbor gene interaction and protein-protein interaction networks of VCAN (GeneMANIA and STRING). (A) VCAN closely interacts with genes that function in tissue development (such as ANOS1, BCAN, FBLN2, and MMP9), those that regulate metastasis by influencing cell-cell interactions, cell adhesion and migration (such as CD44, COL3A1, FBN1, HAPLN1, SELL, and SPARC) and immunity-related genes (such as CCL8, CD14, CXCL12, ITGAM, SELP, TLR1, TLR2, TLR6, and TNFAIP6). (B) VCAN interacted closely with proteins that function in tissue growth, development and regeneration (such as BGN, BCAN, and GPC1) and those involved in growth, adhesion and migration of tumor cells (such as CSPG4, FN1, FBN1, and CDH2) as well as TLR2 involved in innate and adaptive immunity.